Neuroleptic malignant syndrome. When levodopa withdrawal is the cause
- PMID: 2008397
- DOI: 10.1080/00325481.1991.11700900
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause
Abstract
Neuroleptic malignant syndrome has been described in patients receiving dopamine antagonists and in a few patients after withdrawal of dopaminergic antiparkinson therapy. Complications affect almost all organ systems and can be life-threatening. Most patients have fever, altered level of consciousness, bradykinesia, and rigidity. Treatment includes withdrawal of the causative agent and supportive therapy for complications. When withdrawal of a dopaminergic medication is the suspected cause, the agent should be reinstated.
Similar articles
-
Neuroleptic malignant syndrome without neuroleptics.J Clin Psychopharmacol. 1990 Dec;10(6):437-8. J Clin Psychopharmacol. 1990. PMID: 2286714 No abstract available.
-
Neuroleptic malignant syndrome without neuroleptics.Singapore Med J. 2001 Feb;42(2):85-8. Singapore Med J. 2001. PMID: 11358199
-
A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.JAMA. 1985 Nov 15;254(19):2792-5. JAMA. 1985. PMID: 4057489
-
Malignant syndrome in Parkinson's disease: concept and review of the literature.Parkinsonism Relat Disord. 2003 Apr;9 Suppl 1:S3-9. doi: 10.1016/s1353-8020(02)00125-6. Parkinsonism Relat Disord. 2003. PMID: 12735909 Review.
-
[Neuroleptic malignant-like syndrome following levodopa withdrawal].Rev Neurol (Paris). 1990;146(3):215-8. Rev Neurol (Paris). 1990. PMID: 2184486 Review. French.
Cited by
-
Implications of dopaminergic medication withdrawal in Parkinson's disease.J Neural Transm (Vienna). 2022 Sep;129(9):1169-1178. doi: 10.1007/s00702-021-02389-x. Epub 2021 Jul 29. J Neural Transm (Vienna). 2022. PMID: 34324057 Free PMC article.
-
Neuroleptic Malignant Syndrome: A Case of Unknown Causation and Unique Clinical Course.Cureus. 2021 Mar 25;13(3):e14113. doi: 10.7759/cureus.14113. Cureus. 2021. PMID: 33927924 Free PMC article.
-
Serotonin syndrome caused by a moclobemide-clomipramine interaction.BMJ. 1993 Jan 23;306(6872):248. doi: 10.1136/bmj.306.6872.248. BMJ. 1993. PMID: 8443525 Free PMC article. No abstract available.
-
Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development.Brain Commun. 2019 Oct 16;1(1):fcz025. doi: 10.1093/braincomms/fcz025. eCollection 2019. Brain Commun. 2019. PMID: 32954266 Free PMC article. Review.
-
Neuroleptic malignant syndrome and serotonin syndrome: a comparative bibliometric analysis.Orphanet J Rare Dis. 2024 Jun 2;19(1):221. doi: 10.1186/s13023-024-03227-5. Orphanet J Rare Dis. 2024. PMID: 38825678 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources